drugset
drugset / Trial / NCT04976270

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

NCT04976270 ↗

Phase 1 Completed 23 enrolled Lakefront Biotherapeutics NV
RandomizedSequentialQuadruple-blindBasic science

Summary

This study is a phase I, randomized, double-blind, placebo-controlled, single-center, to evaluate the safety, tolerability, and pharmacokinetics (PK) of GLPG3667 after an oral single dose (SD) of GLPG3667 (part 1) and after oral multiple doses (MD) for 13 days of GLPG3667 (part 2) in healthy male subjects.

Timeline

Start
2021-07-20
Primary completion
2022-01-14
Completion
2022-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG3667 Small molecule — Oral

Indications

No indication recorded.